Fibroblast growth factor 21 (FGF21) is a liver-derived endogenous hormone whose pharmacologic analogs exhibit therapeutic promise in obesity, type 2 diabetes, and MASLD by regulating lipid metabolism and enhancing insulin sensitivity (Jin et al., 2023). This evidence concerns the gene FGF21 and metabolic dysfunction-associated steatotic liver disease.